GlycoMimetics (NASDAQ: GLYC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.280 | 0.0300 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of GlycoMimetics (NASDAQ: GLYC) through any online brokerage.
Other companies in GlycoMimetics’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Cellectar Biosciences (NASDAQ:CLRB), Monopar Therapeutics (NASDAQ:MNPR) and PhaseBio Pharmaceuticals (NASDAQ:PHAS).
The latest price target for GlycoMimetics (NASDAQ: GLYC) was reported by Jefferies on Friday, November 12, 2021. The analyst firm set a price target for 4.00 expecting GLYC to rise to within 12 months (a possible 561.92% upside). 1 analyst firms have reported ratings in the last year.
The stock price for GlycoMimetics (NASDAQ: GLYC) is $0.6043 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for GlycoMimetics.
GlycoMimetics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for GlycoMimetics.
GlycoMimetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.